Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.19 (47%) to $2.44 on Friday, which translates to a loss in market cap of $391.4 million, after FDA's Vaccines and Related Biological Products Advisory Committee voted 8-5 with one abstention on Thursday that the company had not gathered enough safety data to support approval of Heplisav, an adjuvanted vaccine for HBV. The PDUFA date is Feb. 24 (see B12).
Dynavax was off $1.73 (41%) for the week, leaving it with a market cap of $436 million.
Nektar Therapeutics (NASDAQ:NKTR) fell $0.80 (12%) to $7.04 on Monday after disclosing in its 10-Q on Nov. 9 that "FDA is exploring whether there is any evidence of a potential cardiovascular class effect related to opioid withdrawal associated with mu opioid antagonists." Nektar is developing naloxegol,